What is the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) model?

Updated: Dec 29, 2020
  • Author: Martha K Terris, MD, FACS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print
Answer

Answer

Cooperberg et al built and validated a model—the Japan Cancer of the Prostate Risk Assessment (J-CAPRA)—for risk prediction in patients receiving primary ADT for prostate cancer. [30] J-CAPRA is scored from 0 to 12 based on the Gleason score, PSA level, and clinical stage. J-CAPRA predicted progression-free survival with a c-index of 0.71 among 13,740 men in a US registry and predicted cancer-specific survival with a c-index of 0.84 among 19,265 men in a Japanese registry. [30]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!